大批中成药将退出市场。 ▲中成药说明书长期以来存在的"尚不明确"面临终结。图/21世纪经济报道 这意味着，现存中成药有效批准文号中，存在安全信息标注问题的批文将面临淘汰。此次监管新政的核 心，是彻底终结中成药说明书长期以来存在的"尚不明确"现象，倒逼药品持有人补齐上市后安全数据短 板。 过去，中成药说明书相关内容普遍出现"尚不明确"表述，当然，这也是行业发展的一个必经过程。中成 药有着悠久的使用历史，很多中成药都是使用多年的老方子，不少人认为，老方子经历了时间的检验， 不良反应等临床试验数据缺乏无关紧要。 并且，过去受限于科研水平和技术手段，对中成药的研究不够深入和全面，难以精准地确定其禁忌、不 良反应以及注意事项等内容，在确定说明书内容时，只能无奈地标注"尚不明确"。 如今，医学科技取得了巨大进步，包括中成药在内的药品研发和监测体系日益完善，通过各种先进的临 床试验方法、大数据分析技术以及长期的用药观察，掌握药品的禁忌与不良反应不再是难事。尤其是智 能模型与药品研发和监测的高效结合，已经有能力对药品的安全性进行全面和准确的评估。 中成药虽然成分复杂，作用机制多样，但目前许多科研机构和企业已经具备了对中成药进 ...

近日，"大批中成药将退出市场"的话题持续引发热议。 距离2026年7月1日的执行节点仅剩半年，国家药监局《中药注册管理专门规定》第七十五条的落地已进 入冲刺阶段，该条款为中成药再注册划定了明确的硬性门槛。 行业将迎来深度洗牌 北京中医药大学卫生健康法治研究与创新转化中心主任邓勇对中国证券报记者表示，距离2026年7月1日 中成药再注册"大限"仅剩半年，行业正经历深度洗牌。 3年期限将至 《中药注册管理专门规定》自2023年7月1日起施行。《专门规定》共11章82条，包括总则、中药注册分 类与上市审批、人用经验证据的合理应用、中药创新药、中药改良型新药、古代经典名方中药复方制 剂、同名同方药、上市后变更、中药注册标准、药品名称和说明书等内容。 《专门规定》第七十五条明确，持有人应当加强对药品全生命周期的管理，加强对安全性风险的监测、 评价和分析，应当参照相关技术指导原则及时对中药说明书【禁忌】【不良反应】【注意事项】进行完 善。中药说明书【禁忌】【不良反应】【注意事项】中任何一项在规定施行之日起满3年后申请药品再 注册时仍为"尚不明确"的，依法不予再注册。 央视此前报道，《2022国家中药监管蓝皮书》显示，截至 ...

此次监管新政的核心，是彻底终结中成药说明书长期以来的"尚不明确"时代，倒逼药品持有人补齐上市 后安全数据短板。中国食品药品监管杂志此前研究显示，2018年版《国家基本药物目录》中268个中成 药品种的465份说明书里，不良反应、禁忌、药物相互作用的标注率仅为20.64%、30.1%和1.07%，大量 品种依靠模糊表述完成上市后的市场流通。而随着再注册大考临近，这种"模糊免责"的模式已彻底失去 生存空间。 2023年2月10日，国家药品监督管理局发布了《中药注册管理专门规定》。该规定于2023年7月1日起施 行，其中第七十五条明确规定，中药说明书【禁忌】、【不良反应】、【注意事项】中任何一项在本规 定施行之日起满3年后申请药品再注册时仍为"尚不明确"的，依法不予再注册。这一被业内称为中成 药"生死条款"的规定将于今年7月1日正式启用。这意味着， 国内现存约5.7万个中成药有效批准文号 中，超70%存在安全信息标注问题的批文将面临淘汰。 ...

Group 1 - The core viewpoint of the article is that a significant number of traditional Chinese medicine (TCM) products will exit the market due to regulatory changes, specifically the enforcement of safety information requirements in product labels [2][3] - The National Medical Products Administration's new regulation, referred to as the "life and death clause" for TCM, will take effect in July 2026, leading to the elimination of products with unclear safety information [2][3] - Over 70% of the approximately 57,000 approved TCM products currently have safety information marked as "unclear," indicating a substantial market contraction ahead [2][3] Group 2 - The new regulation aims to end the era of vague safety information on TCM product labels, compelling manufacturers to provide complete safety data post-market [5] - The automotive industry is experiencing a decline in profit margins, with sales profit rates dropping to a historical low of 4.1% in 2025, reflecting broader economic challenges [5] - Nike is planning to lay off 775 employees in the U.S. as part of a strategy to enhance profitability amid declining sales growth and shrinking profit margins [8]

此次监管新政的核心，是彻底终结中成药说明书长期以来的"尚不明确"时代，倒逼药品持有人补齐上市后 安全数据短板。 2026.01. 27 本文字数：676，阅读时长大约1分钟 据21财经，距2026年7月1日仅剩半年时间，国家药监局《中药注册管理专门规定》第七十五条的落地进入 最后窗口期。 这一被业内称为中成药"生死条款"的规定明确，自2023年7月1日施行满三年起，说明书【禁忌】【不良反 应】【注意事项】任意一项仍标注"尚不明确"的中成药，再注册申请将依法不予通过。这意味着， 国内现 存约5.7万个中成药有效批准文号中，超70%存在安全信息标注问题的批文将面临淘汰。 第 一 财 经 持 续 追 踪 财 经 热 点 。 若 您 掌 握 公 司 动 态 、 行 业 趋 势 、 金 融 事 件 等 有 价 值 的 线 索 ， 欢 迎 提 供 。 专 用 邮 箱 ： bianjibu@yicai.com （注：我们会对线索进行核实。您的隐私将严格保密。） 推荐阅读 地方国资下场低价"扫货"法拍房 中国食品药品监管杂志此前研究显示，2018年版《国家基本药物目录》中268个中成药品种的465份说明 书里，不良反应、禁忌 ...

Group 1 - The core viewpoint of the news is that Tai Long Pharmaceutical has shown a significant increase in trading activity, with a 2.69% rise in stock price and a trading volume of 188 million yuan on January 23 [1] - As of January 23, the financing balance of Tai Long Pharmaceutical reached 290 million yuan, accounting for 7.35% of its market capitalization, indicating a high level of financing activity compared to the past year [1] - The company has a diverse revenue structure, with 70.59% from drug manufacturing, 14.71% from drug research services, and 14.42% from drug material circulation [1] Group 2 - As of September 30, the number of shareholders for Tai Long Pharmaceutical was 40,400, a decrease of 1.08% from the previous period, while the average circulating shares per person increased by 1.09% to 14,190 shares [2] - For the period from January to September 2025, Tai Long Pharmaceutical reported a revenue of 1.187 billion yuan, a year-on-year decrease of 11.47%, and a net profit attributable to shareholders of 25.33 million yuan, down 12.36% year-on-year [2] - The company has distributed a total of 120 million yuan in dividends since its A-share listing, with 23.27 million yuan distributed over the past three years [3]

Core Viewpoint - The company expects a significant decline in net profit for the year 2025, projecting a range of 36 million to 52 million yuan, which represents a decrease of approximately 2.22 billion to 2.38 billion yuan compared to the previous year's profit of about 274 million yuan, indicating a year-on-year decline of 81.02% to 86.86% [1] Group 1: Financial Performance - The expected net profit for 2025 is projected to be between 36 million and 52 million yuan [1] - This represents a decrease of approximately 2.22 billion to 2.38 billion yuan compared to the previous year's profit of about 274 million yuan [1] - The year-on-year decline in profit is estimated to be between 81.02% and 86.86% [1] Group 2: Reasons for Performance Decline - The primary reason for the performance decline is a decrease in operating performance due to the slowdown in the traditional Chinese medicine industry, influenced by industry cycles and changes in market demand [1] - The company anticipates goodwill impairment related to its acquisition of Guizhou Hanfang Pharmaceutical Co., Ltd., which resulted in goodwill of approximately 335 million yuan [1] - Due to the slowdown in market demand for Hanfang Pharmaceutical's products and intensified industry competition, the company plans to recognize a goodwill impairment provision of about 130 million yuan for 2025 [1]

Group 1 - The recent price increase in traditional Chinese medicine and herbal materials has not significantly impacted the company's performance [1] - The company manages a 500,000-acre herbal planting base in Zhangshu, China, which allows for cost control and efficiency improvement [1]

Group 1 - The core viewpoint of the news is that Guangdong Wannianqing Pharmaceutical Co., Ltd. has shown fluctuations in its financing activities and financial performance, indicating potential investment opportunities and risks [1][2]. Group 2 - As of January 22, Guangdong Wannianqing's stock price increased by 0.70%, with a trading volume of 141 million yuan. The financing buy-in amount was 10.76 million yuan, while the financing repayment was 11.04 million yuan, resulting in a net financing buy-in of -284,400 yuan [1]. - The total financing and securities balance for Guangdong Wannianqing reached 116 million yuan, accounting for 3.35% of its market capitalization, which is above the 90th percentile level over the past year [1]. - The company has not engaged in any short selling activities on January 22, with a short selling balance of 0 shares, indicating a lack of bearish sentiment in the market [1]. Group 3 - As of September 30, the number of shareholders for Guangdong Wannianqing was 11,400, a decrease of 7.18% from the previous period. The average circulating shares per person increased by 7.74% to 13,994 shares [2]. - For the period from January to September 2025, Guangdong Wannianqing reported an operating income of 228 million yuan, a slight decrease of 0.14% year-on-year. The net profit attributable to the parent company was -8.13 million yuan, representing a significant decline of 157.65% year-on-year [2]. - Since its A-share listing, Guangdong Wannianqing has distributed a total of 65.6 million yuan in dividends, with 40 million yuan distributed over the past three years [2].

Core Viewpoint - Wohuah Pharmaceutical reported a significant turnaround in profitability for 2025, achieving a net profit of 95.71 million yuan, a year-on-year increase of 162.93% [1][19][25] Financial Performance - The company achieved operating revenue of 817 million yuan, representing a growth of 6.96% year-on-year [1][19] - The net profit attributable to shareholders reached 95.71 million yuan, with a basic earnings per share of 0.17 yuan [1][19] - The fourth quarter net profit was 31.72 million yuan, a quarter-on-quarter increase of 64.2% [1][13] Business Structure - The revenue is heavily concentrated in four proprietary medical insurance products, with cardiovascular system drugs generating 56.88 million yuan, accounting for 69.62% of total revenue [7][21] - The muscle and skeletal system drugs generated 18.25 million yuan, representing 22.34% of total revenue [7][21] - The company’s revenue from the outpatient market (e-commerce, OTC, channel sales) was approximately 10.3 million yuan, making up 12.6% of total revenue [20] Cost Management and Strategy - The company attributed its performance improvement to refined management practices and a strategy focused on cost control and brand development [6][19] - The gross margin for cardiovascular drugs was 83.43%, an increase of 2.66 percentage points from the previous year [8][22] Governance Changes - Wohuah Pharmaceutical officially entered a "no actual controller" status following a divorce settlement between its former actual controller and his ex-wife, each holding 50% of the controlling entity [3][25] - The company has established a "board-centered" governance structure to ensure effective decision-making and management stability [25] Market Reaction - As of January 20, the stock price closed at 7.20 yuan per share, down 6.01% [4][16]